Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Digestive System Diseases

Gland and Hormone Related Diseases

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Prostatic Neoplasms

Breast Neoplasms

Syndrome

Esophageal Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Urinary Bladder Neoplasms

Thyroid Neoplasms

Thyroid Diseases

Carcinoma, Renal Cell

Facies

Head and Neck Neoplasms

Solitary Pulmonary Nodule

Sarcoma

Histiocytoma, Malignant Fibrous

Mesothelioma

Mesothelioma, Malignant

Liposarcoma

Osteosarcoma

Mouth Neoplasms

Carcinosarcoma

Mixed Tumor, Mullerian

Chondrosarcoma

Fibrosarcoma

Histiocytoma

Carcinoma, Bronchogenic

Hemangiosarcoma

Kidney Neoplasms

Carcinoma, Small Cell

Leiomyosarcoma

Phyllodes Tumor

Hemangioma

Adenoma, Pleomorphic

Parathyroid Neoplasms

Otorhinolaryngologic Neoplasms

Pancoast Syndrome

Adenosarcoma

Lymphangiosarcoma

Myosarcoma

Mixed Tumor, Mesodermal

Tracheal Neoplasms

Facial Neoplasms

Esophageal Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Renal Cell Carcinoma

Soft Tissue Sarcoma

Malignant Mesothelioma

Oral Cancer

Malignant Mixed Mullerian Tumor

All Drugs and Chemicals

Antineoplastic Agents

Androgens

Fluorouracil

Belinostat

Parathyroid Hormone

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Histone Deacetylase Inhibitors

Enzyme Inhibitors

300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1

belinostat

250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.

5-Fluorouracil (5-FU)

Topotarget A/S

This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors

Valerio Therapeutics

Nervous System Diseases

Testicular Neoplasms

Rhabdomyosarcoma

Sarcoma, Synovial

Neurofibrosarcoma

Sarcoma, Alveolar Soft Part

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Synovial Sarcoma

Malignant Peripheral Nerve Sheath Tumor

Vaccines

Immunomodulating Agents

Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens

Autologous dendritic cell vaccine

Yuriy Komarov, PhD

The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas

Vaccination is carried out on the planned days ± 3 days

1. All examinations must be performed before the vaccine is administered.

   * Full physical examination.
   * Assessment of vital signs (blood pressure, temperature, heart rate), the general condition of the patient and physical activity.
   * Evaluation of concomitant therapy.
   * Assessment of vital signs.
   * Laboratory safety and immunological indicators
   * Assessment of adverse events, symptoms and syndromes of the disease.
2. Introduction of CV in accordance with the dose determined for a given vaccination (see section 9.2. - procedures for delivery and use)
3. After administration, patients are observed for at least 1 hour. An assessment of vital indicators. Undesirable effects detected at the introduction are recorded.

Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma

Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma

Achieving a six-month time to progression (PFS) 40% of patients receiving ADKV loaded with allogeneic tumor lysate expressing PTA in patients with soft tissue sarcomas

The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works

The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that half of the patients in a group of patients diagnosed with the disease are still alive. In a clinical trial, measuring the median overall survival is one way to see how well a new treatment works

The percentage of patients whose cancer shrinks or disappears after treatment.

Сhanging level of T lymphocytes subpopulation in peripheral blood

N.N. Petrov National Medical Research Center of Oncology

Carcinoma, Squamous Cell

Melanoma

Carcinoma, Basal Cell

Skin Neoplasms

Dermatofibrosarcoma

Neoplasms, Adnexal and Skin Appendage

Neoplasms, Glandular and Epithelial

Skin Diseases

Neoplasms, Squamous Cell

Neoplasms, Fibrous Tissue

Neoplasms, Connective Tissue

Neoplasms, Basal Cell

Dermatofibrosarcoma Protuberans

Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.

A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.

Mohs surgery

Ignacio Garcia-Doval, MD, PhD

REGESMOHS (Registro Español de cirugía de Mohs) aims at describing effectiveness of Mohs surgery, and patient, tumor and technique factors related to adverse events and tumor recurrence.

REGESMOHS is a prospective cohort, including all patients considered for Mohs surgery in participating centers. All consecutive patients are included. The only exclusion criteria are being under 18-years-old or legally incompetent. Pre-planned follow-up is as required by common clinical practice, but at least once a year for the study period.

Spanish Registry of Mohs Surgery

Spanish Registry of Mohs Surgery [Registro Español de Cirugía de Mohs]

Bleeding, infection, abnormal scar, necrosis

Need for admission, type of anesthesia, number of surgical steps, participating doctors,time in surgery room.

presence of: abnormal scar, ectropion, nostril alteration, oral sphincter incompetence,other

Roche Pharma AG

Fundación Academia Española de Dermatología

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics
Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma	NCT01883518	Sarcoma Neoplasms, Conn...	Autologous dend...	18 Years -	N.N. Petrov National Medical Research Center of Oncology
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics
Spanish Registry of Mohs Surgery	NCT02310503	Skin Neoplasms Carcinoma, Basa... Carcinoma, Squa... Dermatofibrosar... Melanoma Histiocytoma, M... Neoplasms, Adne...	Mohs surgery	18 Years -	Fundación Academia Española de Dermatología
Spanish Registry of Mohs Surgery	NCT02310503	Skin Neoplasms Carcinoma, Basa... Carcinoma, Squa... Dermatofibrosar... Melanoma Histiocytoma, M... Neoplasms, Adne...	Mohs surgery	18 Years -	Fundación Academia Española de Dermatología

Spots Global Cancer Trial Database for histiocytoma, malignant fibrous